SCHEMBL514979

SCHEMBL514979

Cc1ccc([N+](=O)[O-])c(N2CCC(=Cc3nnc(C)o3)CC2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 9/20 0.48
CYP3A4 P08684 1/20 0.43
MAPT P10636 3/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPK1 P28482 2/20 0.41
POLB P06746 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
RAB9A P51151 1/20 0.40
LMNA P02545 1/20 0.36
CYP1A2 P05177 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 1/20 0.33
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
TNNI3 P19429 1/20 0.33
TNNT2 P45379 1/20 0.33
TNNC1 P63316 1/20 0.33
KMT2A Q03164 1/20 0.33
CTSB P07858 1/20 0.33
CTSH P09668 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL512661 0.87 GRM5 (0.47) GRM5CYP3A4MAPTALDH1A1MAPK1
SCHEMBL512730 0.84 GRM5 (0.45) GRM5CYP3A4MAPTALDH1A1MAPK1
SCHEMBL512658 0.83 GRM5 (0.48) GRM5CYP3A4MAPTALDH1A1MAPK1
SCHEMBL512243 0.81 GRM5 (0.46) GRM5CYP3A4MAPTALDH1A1MAPK1
SCHEMBL514928 0.79 GRM5 (0.46) GRM5CYP3A4MAPTALDH1A1MAPK1
SCHEMBL512667 0.79 GRM5 (0.48) GRM5CYP3A4MAPTALDH1A1MAPK1
SCHEMBL512866 0.78 GRM5 (0.48) GRM5CYP3A4MAPTALDH1A1MAPK1
SCHEMBL513812 0.78 GRM5 (0.45) GRM5CYP3A4MAPTPOLBRAB9A
SCHEMBL512619 0.77 GRM5 (0.46) GRM5CYP3A4MAPTALDH1A1MAPK1
SCHEMBL512328 0.76 GRM5 (0.48) GRM5CYP3A4MAPTALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2477981-A1 HETEROCYCLIC MGLU5 ANTAGONISTS Recordati Ireland Limited (IE) 2012-07-25 EP claimed
US-20120028931-A1 HETEROCYCLIC M-GLU5 ANTAGONISTS RECORDATI IRELAND LIMITED (IE) 2012-02-02 US claimed
US-20120028931-A1 HETEROCYCLIC M-GLU5 ANTAGONISTS RECORDATI IRELAND LIMITED (IE) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028931-A1 HETEROCYCLIC M-GLU5 ANTAGONISTS OPRM1, GRM5, OPRD1 GRM5 2/4885CYP3A4 1085/4885MAPT 2573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.